Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...
HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...
On Monday, Veru Inc (VERU) stock saw a decline, ending the day at $0.64 which represents a decrease of $-0.57 or -47.11% from the prior close of $1.21. The stock opened at $0.64 and touched a low of ...
Versant Ventures continues to invest in the increasingly competitive obesity space, this time launching Helicore with $65 ...
The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...
William Wood, an analyst from B.Riley Financial, maintained the Buy rating on Veru (VERU – Research Report). The associated price target ...
Oppenheimer reiterated its Outperform rating and $5.00 price target for Veru Inc. (NASDAQ:VERU) shares, following the ...
Pfizer Inc. (NYSE:PFE) revealed results from the Phase 3 BREAKWATER trial evaluating Braftovi (encorafenib) in combination ...
Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.
Positive data for Veru Inc.’s enobosarm lend more weight to the potential progress of the company’s body-mass preservation program in patients taking Wegovy (semaglutide). Top-line data of the phase ...
On Monday, AT&T Inc T reported better-than-expected fourth-quarter results. The company posted operating revenues of $32.30 ...
Veru says its muscle-maintaining drug preserved more lean mass in older patients taking a GLP-1, but skittish investors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback